Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Gabrielle Poirier, BS

Entasis Therapeutics

Disclosure(s): Entasis Therapeutics: Ownership Interest, Stocks/Bonds

Poster(s):

675 - Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET